Medicare Enrolled
Dr. Irfan Mirza, MD
Hematology & Oncology · Chicago, IL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Mirza from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mirza?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Mirza
Dr. Irfan Mirza is a hematology & oncology specialist in Chicago, IL, with 21 years of NPI registration. Based on federal Medicare data, Dr. Mirza performed 190,403 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Mirza received a total of $565,184 from 67 pharmaceutical and/or device companies across 863 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Mirza is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 21 years of NPI registration
▲ Top 6% volume in IL
$565,184 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗190,403
Medicare services
Top 6% in IL for hematology & oncology
Not available
Unique patients (not deduplicated)
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Filgrastim injection (Nivestym) for white blood cells An injection of the biosimilar medication filgrastim-aafi (Nivestym) at a dose of 1 microgram. |
59,040 | $0 | $2 |
| Pembrolizumab injection (Keytruda) | 25,700 | $43 | $137 |
| Filgrastim injection (Zarxio) for white blood cells An injection of the biosimilar medication filgrastim-sndz (Zarxio) with a dosage of 1 microgram. |
24,000 | $0 | $2 |
| Oxaliplatin chemotherapy injection This procedure involves the administration of oxaliplatin, a chemotherapy medication, via injection. The dosage specified is 0.5 mg. |
22,500 | $0 | $33 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
14,590 | $2 | $20 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
14,550 | $0 | $6 |
| Paclitaxel chemotherapy injection | 7,734 | $0 | $5 |
| Denosumab injection (Prolia/Xgeva) | 2,880 | $19 | $69 |
| Romiplostim injection, 10 micrograms An injection of romiplostim containing 10 micrograms of the medication. |
2,649 | $73 | $238 |
| Iron infusion (Monoferric) | 2,600 | $17 | $69 |
| Anti-nausea injection (ondansetron/Zofran) | 2,462 | $0 | $3 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,010 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,290 | $1 | $114 |
| Injection, leucovorin calcium, per 50 mg | 1,163 | $3 | $25 |
| Pegfilgrastim-apgf injection An injection of pegfilgrastim-apgf, a biosimilar medication. The dose specified is 0.5 mg. |
1,008 | $92 | $824 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
768 | $100 | $231 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
716 | $2 | $13 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
605 | $11 | $93 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
580 | $107 | $686 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
461 | $23 | $152 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
336 | $87 | $1,348 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
281 | $13 | $105 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
278 | $66 | $168 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
247 | $66 | $157 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
211 | $2 | $300 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
187 | $7 | $431 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
141 | $23 | $156 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
126 | $54 | $334 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
121 | $140 | $325 |
| Enhanced Oncology Model monthly payment This code represents the monthly enhanced oncology services payment under the Enhancing Oncology Model. It covers the administrative payment for enhanced services provided to eligible patients. |
118 | $70 | $70 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
112 | $144 | $412 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
110 | $1 | $17 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
109 | $49 | $304 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
86 | $1 | $7 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
79 | $59 | $205 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
67 | $213 | $1,726 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
63 | $46 | $281 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
61 | $16 | $91 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
57 | $27 | $249 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
53 | $1 | $9 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
52 | $99 | $232 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
41 | $2 | $19 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
39 | $4 | $25 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
35 | $16 | $97 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
25 | $15 | $108 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
23 | $21 | $111 |
| New patient office visit, complex (60-74 min) | 20 | $175 | $432 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
19 | $109 | $297 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
2.1% high complexity
96.9% medium
1.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$565,184
Total received (2018-2024)
Avg $80,741/year across 7 years
Top 1% in IL for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
67
Companies
863
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$57,128
2023
$98,506
2022
$52,691
2021
$88,660
2020
$60,012
2019
$109,507
2018
$98,679
Payments by company (2024)
Regeneron Healthcare Solutions, Inc.
$24,914
BeiGene USA, Inc.
$15,740
ABBVIE INC.
$14,962
Novartis Pharmaceuticals Corporation
$452
PFIZER INC.
$175
Celgene Corporation
$163
E.R. Squibb & Sons, L.L.C.
$155
Gilead Sciences, Inc.
$115
AstraZeneca Pharmaceuticals LP
$80
Amneal Pharmaceuticals LLC
$74
Incyte Corporation
$55
Genentech USA, Inc.
$50
Merck Sharp & Dohme LLC
$39
Immunocore Limited
$24
Janssen Biotech, Inc.
$24
Eisai Inc.
$23
GlaxoSmithKline, LLC.
$23
EMD Serono, Inc.
$20
Daiichi Sankyo Inc.
$19
Kyowa Kirin, Inc.
$17
Iovance Biotherapeutics, Inc.
$6
Top 3 companies account for 97.4% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$210,043
Regeneron Healthcare Solutions, Inc.
$81,622
Boehringer Ingelheim Pharmaceuticals, Inc.
$67,688
BeiGene USA, Inc.
$62,562
GENZYME CORPORATION
$54,430
ABBVIE INC.
$50,509
Mirati Therapeutics, Inc.
$14,550
AbbVie Inc.
$7,950
Genentech USA, Inc.
$4,118
Heron Therapeutics, Inc.
$1,800
Novartis Pharmaceuticals Corporation
$1,455
R-Pharm US LLC
$1,325
Adaptive Biotechnologies Corporation
$750
Merck Sharp & Dohme Corporation
$526
Celgene Corporation
$514
PFIZER INC.
$502
E.R. Squibb & Sons, L.L.C.
$459
TG THERAPEUTICS, INC.
$411
Pharmacyclics LLC, An AbbVie Company
$311
Gilead Sciences, Inc.
$303
Rigel Pharmaceuticals, Inc.
$298
Amgen Inc.
$297
Seagen Inc.
$286
Takeda Pharmaceuticals U.S.A., Inc.
$189
AbbVie, Inc.
$160
GlaxoSmithKline, LLC.
$158
Lilly USA, LLC
$157
Boston Scientific Corporation
$140
Epizyme, Inc.,
$137
Merck Sharp & Dohme LLC
$124
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$101
EMD Serono, Inc.
$100
G1 Therapeutics, Inc.
$100
Karyopharm Therapeutics Inc.
$96
Deciphera Pharmaceuticals Inc.
$80
Amneal Pharmaceuticals LLC
$74
Incyte Corporation
$55
Janssen Biotech, Inc.
$45
Daiichi Sankyo Inc.
$45
Agios Pharmaceuticals, Inc.
$44
Organon LLC
$43
Astellas Pharma US Inc
$41
Puma Biotechnology, Inc.
$41
Epizyme, Inc.
$39
Exelixis Inc.
$38
Verity Pharmaceuticals Inc.
$38
Dova Pharmaceuticals
$33
SERVIER PHARMACEUTICALS LLC
$30
Secura Bio, Inc.
$29
Foundation Medicine, Inc.
$27
Intuitive Surgical, Inc.
$26
Pharmacyclics LLC, an AbbVie Company
$25
Kite Pharma, Inc.
$25
Immunocore Limited
$24
CTI BioPharma Corp.
$24
Eisai Inc.
$23
Janssen Pharmaceuticals, Inc
$19
Melinta Therapeutics, LLC
$19
EISAI INC.
$17
Alexion Pharmaceuticals, Inc.
$17
Kyowa Kirin, Inc.
$17
Apellis Pharmaceuticals, Inc.
$17
AMAG Pharmaceuticals, Inc.
$15
Pharmacosmos Therapeutics Inc.
$15
NOVARTIS PHARMACEUTICALS CORPORATION
$14
Fortovia Therapeutics, Inc.
$6
Iovance Biotherapeutics, Inc.
$6
Top 3 companies account for 63.6% of all-time payments
Associated products mentioned in payments ›
ABECMA · ADAKVEO · ADCETRIS · ALIMTA · ALUNBRIG · ARZERRA · ASPARLAS · AVASTIN · Abraxane · Alecensa · Amtagvi · Avastin · BAVENCIO · BEVESPI AEROSPHERE · BOSULIF · BRUKINSA · Bavencio · Blincyto · CABLIVI · CALQUENCE · COSELA · Cabometyx · Da Vinci Surgical System · Doptelet · EPKINLY · Empaveli · Enhertu · FARYDAK · FERAHEME · FOUNDATIONONE · Fabhalta · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · Ixempra · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kadcyla · Kyprolis · LENVIMA · LIBTAYO · LORBRENA · LUTATHERA · LYNPARZA · Lenvima · LifeVest · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · NINLARO · Non-Covered Product · Nplate · OJJAARA · ONTRUZANT · ONUREG · OPDIVO · OPDUALAG · PIQRAY · PROMACTA · Perjeta · Polivy · Pomalyst · Poteligeo · QINLOCK · REBLOZYL · RYBREVANT · Rezzayo · SANCUSO · SANDOSTATIN · SARCLISA · SCEMBLIX · SOLIRIS · SUSTOL · SUTENT · Soltamox · SpyGlass · TABRECTA · TAGRISSO · TALZENNA · TASIGNA · TAZVERIK · TECENTRIQ · TIBSOVO · TUKYSA · Tavalisse · Tazverik · Tibsovo · Trelstar · Trodelvy · UKONIQ · VENCLEXTA · VERZENIO · VOTRIENT · Venclexta · Vonjo · XALKORI · XARELTO · XOSPATA · XPOVIO · Yescarta · ZEJULA · clonoSEQ
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
336
County median income
$81,797
Nearest hospital to ZIP centroid (approximate)
AMITA HEALTH RESURRECTION MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Mirza is a mixed practice specialist, with above-average Medicare volume (top 6% in IL), with 21 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Mirza experienced with filgrastim injection (nivestym) for white blood cells?
Based on Medicare claims data, Dr. Mirza performed 59,040 filgrastim injection (nivestym) for white blood cells services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Mirza receive payments from pharmaceutical companies?
Yes. Dr. Mirza received a total of $565,184 from 67 companies across 863 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mirza's costs compare to other hematology & oncology specialists in Chicago?
Dr. Mirza's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mirza) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Chicago
Browse hematology & oncology specialists in Chicago ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in IL
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in IL
Which IL hematology & oncology specialists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Regeneron Healthcare Solutions, Inc. Payments to Doctors
See all physicians who received payments from Regeneron Healthcare Solutions, Inc.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology